Pete Hegseth’s Military Testosterone Policy, What It Proposes and Why It Matters
Quick Answer
Defense Secretary Pete Hegseth announced in July 2025 that the U.S. military would implement mandatory annual testosterone deficiency screenings for all active-duty service members aged 30 and older.
The policy is framed as a health and readiness initiative, not a performance-enhancement program, and includes optional hormone therapy for those diagnosed with deficiencies. It has sparked significant debate over medical necessity, cost, and its implications for military policy, including a legal challenge in a lawsuit regarding transgender troops.Key Facts
- Mandatory annual testosterone deficiency screenings apply to all active-duty U.S. service members aged 30 and older.
- The policy was announced by Defense Secretary Pete Hegseth in 2025.
- The initiative aims to optimize health and performance, not artificial enhancement.
- Optional hormone therapy is available for those with diagnosed deficiencies.
- The policy has drawn criticism from lawmakers like Sen. Mark Kelly, who stated the military "doesn't need more testosterone, it needs better leadership."
- A federal judge questioned the policy's distinction from transgender treatment in a related lawsuit.
Why Hegseth Pushed for Testosterone Screenings Now
The Rationale Behind the Policy
The official justification for mandatory testosterone screenings rests on two pillars: military readiness and individual soldier health. Defense Secretary Pete Hegseth has framed the initiative as a proactive health measure, arguing that undiagnosed testosterone deficiencies can impair physical performance, cognitive function, and overall resilience—critical attributes for service members.
By screening those 30 and older, the Pentagon aims to catch deficiencies early and offer optional hormone therapy to restore optimal levels. This is not presented as a program for artificial enhancement.The policy explicitly distinguishes between treating medical deficiencies and pursuing performance gains beyond normal physiological ranges. The screenings are intended to identify service members whose testosterone falls below clinically defined thresholds, not to encourage supraphysiological levels that might confer unfair advantages.Political and Cultural Context
The announcement comes amid a broader push by the Trump administration to reshape military culture and policy. Hegseth, a former Fox News host and veteran, has been a vocal advocate for what he calls "warrior culture" in the armed forces.
The testosterone screening policy aligns with a narrative that physical toughness and readiness should be prioritized, contrasting with what some critics view as unnecessary bureaucracy or social experimentation. However, the timing and framing have invited scrutiny.Sen. Mark Kelly, a former astronaut and Navy pilot, publicly opposed the policy, arguing that the military's challenges are about leadership and strategy, not hormone levels.Kelly's criticism reflects a broader concern: that the policy could be a distraction from more pressing issues like modernization, recruitment, and retention.Legal and Ethical Questions
A federal judge has questioned the policy's distinction from transgender treatment in a related lawsuit. This raises a significant legal question: if the military is now screening for and treating testosterone deficiencies, does that create a contradictory stance on hormone therapies?
The lawsuit, which challenges the Pentagon's ban on transgender troops, argues that the new policy undermines the rationale for excluding individuals who may require hormone therapy for gender transition. The judge's inquiry suggests that the policy may face legal hurdles if it cannot be consistently applied.If the military is willing to provide hormone therapy for age-related testosterone decline, why not for gender dysphoria? The answer, according to Hegseth's office, is that the two serve different purposes—one is medical treatment, the other is elective.But critics argue this distinction is weak and could be challenged in court.How the Screening Program Will Work
Eligibility and Implementation
Based on the available information, the policy applies to all active-duty service members aged 30 and older. The screenings are annual, meaning every eligible soldier will undergo a blood test once per year to measure testosterone levels.
The program is mandatory, with no opt-out provision, though the subsequent hormone therapy is optional for those diagnosed with deficiencies. The exact thresholds for "deficiency" have not been publicly detailed, but standard clinical guidelines typically define low testosterone as below 300 nanograms per deciliter (ng/dL) for adult men.The military may adopt similar or stricter criteria given the physical demands of service. Service members who fall below the threshold will be offered hormone replacement therapy, which could include testosterone injections, gels, or patches.Cost and Logistics
Implementing a mandatory screening program across the entire active-duty force—approximately 1.3 million personnel—is a significant logistical and financial undertaking. Annual blood tests for testosterone require laboratory capacity, sample collection, and data management.
The Pentagon has not disclosed the program's budget, but estimates based on civilian healthcare costs suggest it could run into tens of millions of dollars annually. The optional therapy component adds further costs.Testosterone replacement therapy can range from $30 to $500 per month depending on the method and dosage. If a significant portion of screened individuals are found to have deficiencies, the military could face substantial ongoing pharmaceutical expenses.However, proponents argue that the long-term benefits—fewer injuries, better performance, lower disability rates—could offset these costs.Comparison to Existing Military Health Programs
The military already conducts mandatory health screenings for various conditions, including hearing loss, vision, and mental health. The testosterone policy is notable because it targets a hormone level that declines naturally with age, rather than a disease or injury.
This blurs the line between preventive medicine and performance optimization. Some service members may welcome the opportunity to address low testosterone, which can cause fatigue, depression, and reduced muscle mass.Others may view it as unnecessary medicalization of normal aging. The optional nature of therapy means that individuals can decline treatment even if diagnosed with a deficiency, preserving personal autonomy.Reactions and Controversies Surrounding the Policy
Political Pushback
The policy has become a lightning rod for political debate. Critics on the left argue that it is a misguided attempt to impose a hyper-masculine ideal on the military.
Sen. Mark Kelly's comment that the military "doesn't need more testosterone, it needs better leadership" encapsulates this view.Kelly, a respected figure with military and spaceflight experience, questions whether the policy addresses real readiness gaps or simply feeds a cultural narrative. Republican supporters, by contrast, have largely praised the initiative as a common-sense health measure.They argue that ensuring optimal hormone levels is part of maintaining a fit and ready force. The policy also resonates with broader conservative themes of strength, self-reliance, and rejecting what they see as progressive social experiments in the military.Medical and Scientific Scrutiny
Endocrinologists and military health experts have raised several concerns. First, the evidence linking testosterone therapy to improved military performance is mixed.
While low testosterone can impair function, the benefits of supplementation for individuals with borderline levels are less clear. Some studies suggest that testosterone therapy may increase cardiovascular risk, particularly in older men.Second, the mandatory nature of screening raises ethical questions. Service members may feel pressured to accept therapy if diagnosed, even if they are asymptomatic.The military's hierarchical culture can make it difficult for individuals to decline recommended treatments without fear of stigma or career consequences. Third, the age threshold of 30 is relatively low.Testosterone levels typically begin to decline around age 30-40, but most men remain within normal ranges well into their 50s. The policy may identify many individuals who are healthy but fall slightly below an arbitrary cutoff, leading to unnecessary treatment.Connection to the Transgender Troop Ban
The most legally consequential controversy involves the transgender troop ban. The Trump administration reinstated a ban on transgender individuals serving openly in the military, arguing that they may require medical treatments that could affect readiness.
The new testosterone policy directly contradicts this rationale, as it actively promotes hormone therapy for age-related deficiencies. The lawsuit challenging the ban has seized on this contradiction.If the military is willing to provide testosterone therapy for some service members, the argument goes, it cannot categorically exclude those who need similar treatments for gender transition. The judge's questioning suggests that the court is taking this argument seriously, and the policy could be a key factor in the lawsuit's outcome.What This Means for Military Readiness and Culture
Potential Benefits for the Force
Proponents argue that the policy will improve readiness by addressing a common but underdiagnosed condition. Low testosterone affects an estimated 2-4% of men under 50, and the proportion increases with age.
In a military force where physical performance is critical, even marginal improvements in strength, endurance, and cognition could have operational benefits. The optional therapy component also gives commanders a tool to manage individual health proactively.Rather than waiting for a service member to report fatigue or declining performance, the screening can identify potential issues early. This could reduce injury rates and improve long-term career outcomes for older service members.Risks and Unintended Consequences
However, the policy carries risks. If implemented poorly, it could stigmatize low testosterone, leading to pressure on service members to accept therapy they do not need.
It could also create a two-tier system where those who receive therapy have an advantage over those who do not, even if both are within normal physiological ranges. There is also the question of cost-effectiveness.The military faces budget constraints and competing priorities, including modernization and retention bonuses. Spending millions on testosterone screening and therapy may not be the most efficient way to improve readiness, especially if the benefits are marginal.Long-Term Cultural Impact
The policy may reinforce a culture that equates masculinity with physical toughness. This could alienate service members who do not fit that mold, including women, older personnel, and those with medical conditions that affect hormone levels.
It may also discourage reporting of health issues, as service members may fear being labeled as deficient. On the other hand, normalizing testosterone screening could reduce stigma around hormone health.If the policy is framed as routine medical care, it may encourage service members to take a more proactive approach to their overall health. The key will be in how the program is communicated and implemented on the ground.Frequently Asked Questions
Is the testosterone screening mandatory for all service members?
According to the policy announced by Defense Secretary Pete Hegseth, mandatory annual screenings apply to active-duty service members aged 30 and older. It is not optional for those who meet the age and service criteria.
Will service members be forced to take testosterone therapy if they have low levels?
No. The policy states that hormone therapy is optional for those diagnosed with testosterone deficiency.
Service members can decline treatment even if their levels fall below the clinical threshold.How does this policy relate to the ban on transgender troops?
A federal judge has questioned the policy's consistency with the transgender troop ban. The lawsuit argues that if the military provides hormone therapy for age-related deficiencies, it cannot logically exclude transgender individuals who also require hormone therapy.
What are the potential health risks of testosterone therapy?
Testosterone replacement therapy can increase the risk of cardiovascular events, sleep apnea, and prostate issues. The military has not publicly addressed how it will monitor these risks in service members who opt for therapy.
When did the policy take effect?
The policy was announced by Hegseth in 2025. Based on the available information, implementation details and specific timelines have not been fully disclosed to the public.
Reference Notes
Information in this article is based on publicly available sources. Some details may change over time.
Verify with official sources before acting.